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Evaluation of the G protein coupled receptor-75 
(GPR75) in age related macular degeneration
Christian G  Sauer, Karen W hite, H eidi Stohr, T iem o G rim m , A m y H utchinson,
Paul S Bernstein, Richard Allan Lewis, Francesca Simonelli, Daniel Pauleikhoff,
Rando Allikmets, Bernhard H  F W eber
Abstract
B ackground—A long term project was 
initiated to identify and to characterise 
genes that are expressed exclusively or 
preferentially in the retina as candidates 
for a genetic susceptibility to age related 
macular degeneration (AM D). A  tran­
script represented by a cluster o f  five 
human expressed sequence tags (ESTs) 
derived exclusively from  retinal cDNA 
libraries was identified.
M ethods—Northern blot and RT-PCR 
analyses confirmed preferential retinal 
expression o f the gene, which encodes a G 
protein coupled receptor, GPR75. Follow­
ing isolation o f  the full length cDNA and 
determination o f  the genomic organis­
ation, the coding sequence o f GPR75 was 
screened for mutations in 535 AMD 
patients and 252 controls from Germany, 
the United States, and Italy. Employed 
methods included single stranded confor­
mational polymorphism (SSCP) analysis, 
denaturing high performance liquid chro­
matography (DHPLC), and direct se­
quencing.
Results—Nine different sequence varia­
tions were identified in patients and 
control individuals. Three o f these 
(-30A>C, 150G>A, and 346G>A) likely 
represent polymorphic variants. Each o f 
six alterations (-4G>A, N78K, P99L, 
S108T, T135P, and Q234X) were found 
once in single AMD patients and were 
considered variants that could affect the 
protein function and potentially cause 
retinal pathology.
Conclusion—The presence o f six potential 
pathogenic variants in a cohort o f 535 
AMD patients alone does not provide sta­
tistically significant evidence for the as­
sociation o f sequence variation in GPR75 
with genetic predisposition to AMD. How­
ever, a possible connection between the 
variants and age related retinal pathology 
cannot be discarded. Functional studies 
are needed to clarify the role o f GPR75 in 
retinal physiology.
(BrJ Ophthalmol 2001;85:969-975)
One challenge in molecular genetic research 
today involves the discovery and characterisa­
tion o f genes that underlie com m on disorders 
with complex patterns o f  inheritance. In 
ophthalmic genetics, such a challenge is posed 
by age related macular degeneration (A M D ), 
which represents the most com m on cause o f
visual impairment in the population over 65 
years o f  age.1 2 The disorder is characterised by 
retinal drusen, abnormal pigmentation o f the 
retinal pigment epithelium (R P E ), and geo­
graphic atrophy and/or choroidal neovasculari- 
sation in association with advancing age.3 
Numerous environmental contributors such as 
sun exposure,4 hypertension,5 cigarette smok- 
ing,6 7 and dietary factors8 9 have been sug­
gested; however, genetic predisposition ap­
pears to be the most important risk factor.10-12 
Elucidation o f  the genetic components will 
lead to a better understanding o f the patho­
physiology o f  A M D  and, in turn, may result in 
the development o f  novel preventive therapies.
Application o f  conventional gene identifica­
tion approaches, such as positional cloning or 
positional candidate gene analysis, to identify 
genetic factors conferring susceptibility to 
A M D  has been hampered by the considerable 
clinical heterogeneity o f  the condition even in 
the same family, by the scarcity o f  families with 
several living aVected members due to the late 
age at onset, and by the lack o f  penetrance in 
younger members o f  families in which older 
individuals may manifest the trait. Thus, most 
studies to date have been limited to screening 
A M D  patients for genetic variation in genes 
implicated in monogenic retinopathies with 
similar phenotypes (for a review, see Yates and 
M oore13). Thus far, no associations have been 
found between A M D  and the genes underlying 
several dominant Mendelian retinal disorders 
with either atrophic or disciform macular 
degeneration as a prominent feature: Sorsby 
fundus dystrophy,14 Best vitelliform macular 
dystrophy,15-17 and Doyne honeycom b retinal 
dystrophy/Malattia Leventinese.18 Screening of 
the photoreceptor specific ATP binding cas­
sette transporter gene, A B C A 4  (formerly 
A B C R ), responsible for Stargardt disease,19 has 
revealed statistically significant association o f 
at least two heterozygous mutations in A B C A 4  
with A M D .20 21 The extent o f  the contribution 
o f  these and other A B C A 4  variants to A M D  
remains to be determined; however, A M D  
associated genetic variation in A B C A 4  has 
been documented in a fraction o f  A M D  
patients, suggesting the contributions o f  other 
yet unidentified genes.22 23
We have initiated a long term project to 
characterise systematically a pool o f  genes that 
can be assessed for their role in predisposition 
to A M D .24 Reasoning that good candidates are 
those genes that are exclusively or preferen­
tially expressed in the human retina, we 
searched the Unigene gene indexing database
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*PCR conditions were 94°C, 5 minutes; 30 cycles of 94°C, 30 seconds, TA, 30 seconds, 72°C, 30 
seconds; 72°C, 5 minutes.
for clusters com posed o f  ESTs derived entirely 
or predominantly from retinal cD N A  libraries, 
and we determined their expression profile in 
vitro.24 We identified an EST cluster Hs.40763 
that contains five retina derived ESTs and con­
firmed by northern blot and reverse transcrip­
tion (R T ) P C R  analysis that it is expressed 
specifically in retina and brain. Assembly and 
subsequent analysis o f  the full length transcript 
have revealed that it encodes a G  protein cou­
pled receptor. M embers o f  this large family o f 
transmembrane proteins, o f  which rhodopsin 
was the first identified,25 mediate signal trans­
duction and are involved in diverse hereditary 
and sporadic diseases (reviewed by Strader et 
al26). Because the expression profile and poten­
tial functional properties made it a candidate 
for involvement in A M D , we screened it for 
mutations in a large cohort o f  affected 
individuals and ethnically and age matched 
controls.
Materials and methods
CDNA CLONING AND DETERMINATION OF GENE 
STRUCTURE
A cluster o f  five EST sequences derived from 
three different retinal cD N A  clones (IM AGE 
clone nos 222124, 363848, 363252) was 
retrieved under accession number Hs.40763 as 
part o f  a search under the term “ eye”  in the 
Unigene Human Sequences Collection (http:// 
www.ncbi.nlm.hih.gov/Unigene).24 cD N A 
IM AG E clone 222124 was obtained from the 
U K H G M P  Resource Centre (Hinxton, Cam­
bridge, U K ), and the complete D N A  sequence
o f  the insert was determined with the Thermo 
Sequenase radiolabelled terminator cycle se­
quencing kit (Amersham, Life Science). To 
extend the resulting sequence to the transcrip­
tion start site, 5 '-RACE was performed on total 
human retinal RN A with the 5'-RACE kit, Ver­
sion 2 (G ibco BRL). First strand cD N A  
synthesis with primer 91.S8 (Table 1) was fol­
lowed by two subsequent P C R  reactions with 
nested primers 91.S4 (Table 1) and 91.S5 (5'- 
T G C  T C C  C C A  A A A ATA C T C  A G -3 '). The 
resulting PC R  products were separated elec- 
trophoretically on an agarose gel, excised, puri­
fied with the QIAexII Gel Extraction Kit (Qia- 
gen), and sequenced directly. To obtain the 
genom ic sequence, we screened the RCPI-1 
PAC library (kindly provided by P de Jong, 
Roswell Park Cancer Institute, Buffalo, NY) 
with a radiolabelled 2057 bp cD N A  insert 
from IM AG E clone 222124. Positive PAC 
clone dJ302H14 was partially sequenced and 
the genomic, and cD N A  sequences were 
aligned with MacVector Sequence analysis 
program Version 4.1.4 (Kodak) to determine 
the exon-intron structure (Fig 1). We subjected 
the deduced protein sequence to homology 
searches with the BLASTP program (http:// 
http://www.ncbi.nlm.nih.gov/BLAST/) and 
used the TMHMM program o f  the Husar 
package (http://genome.dkfz-heidelberg.de/) 
for prediction o f the transmembrane domains.
EXPRESSION ANALYSES
RT-PCR was performed as described previ­
ously.24 Briefly, total RN A was extracted from 
human liver, lung, uterus, cerebellum, brain 
stem, prostate, retinal pigment epithelium, and 
retina tissue with the R N A  Clean system 
(Hybaid). After treatment with the DNA-free 
kit (Am bion) to remove residual genomic 
D N A , 1-2 ^l volumes o f each preparation and 
1-2 ^l volumes o f commercially obtained total 
R N A from heart, kidney, placenta, and thymus 
(Am bion) were reverse transcribed with the 
Superscript preamplification system (Gibco 
BRL), diluted 1:5, and subjected to P C R  with 
oligonucleotide primers 91.S4 (Table 1) and 
91.R13 (5 '-G G T  C C G  G AC T G C  G AG  
A TG -3 ') resulting in a 357 bp product. To nor­
malise for variations in the amount o f  input 
RN A and synthesised cD N A  from each tissue, 
control P C R  reactions were conducted on 2
Sauer, White, Stohr, et al
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Figure 1 Diagrammatic representation of the genomic organisation of GPR75 and PCR amplification of the coding 
region of the gene. The exon/intron structure is given in relative spacing with coding sequences and untranslated regions 
represented by black and shaded boxes, respectively. Mutation analysis of the 1623 bp of coding sequences was done with 
overlapping amplicons as indicated. Primer sequences and PCR conditions are given in Table 1.
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Figure 2 Expression analysis of GPR75. (A) RT-PCR 
showing expression in retina and brain tissue and (B) 
northern blot detecting a 6.6 kb transcript in human 
cerebellum and retina.
o f  diluted first strand cD N A  with primer pair 
G U SB6F (5 '-G A T C C A  C C T  C T G  ATG  
T T C  AC -3') and G U SB 7R (5 '-C C T  T T A  
G T G  T T C  C C T  G C T  A G -3 ') amplifying the 
constitutively expressed P glucuronidase 
(GUSB) gene.27 The G U SB 6F/G U SB 7R am­
plification spans exon 11 and 12 o f the human 
gene and results in a 454 bp fragment in cD N A 
template.
For northern blot analysis, total RN A was 
isolated from human lung, cerebellum, retina, 
uterus, liver, heart, peripheral b lood  lym­
phocytes, and a human RPE cell line 
(ARPE19) with the RN A Clean System 
(Hybaid). In each lane 12 ^g o f  total R N A  was 
separated electrophoretically in a 1.2% agarose 
gel in the presence o f  formaldehyde and 
blotted onto a nylon membrane. A  615 bp 
P C R  fragment amplified from IM AG E clone 
222124 with oligonucleotide primer pair 
91.R4/91.S1 (Table 1) and a 270 bp fragment 
amplified from PAC clone dJ302H14 with the 
oligonucleotide primers 3U T R -F  (5'-AAG 
T G G  A A A T G G  G C A  G A A  AG -3') and 
3U T R -R  (5 '-TT A  C G C  A A A G G A  A C A 
AA G -3') were used for filter hybridisations in
0.5 m M  sodium phosphate buffer, pH  7.2; 7% 
SDS, 1 m M  ED TA at 65°C .28
MUTATION ANALYSIS 
Subjects
A total o f  535 individuals with A M D  and 252 
unaffected controls, matched by age and 
ethnicity were studied. These subjects have 
been ascertained in Germany, the United 
States, and Italy and have been described pre­
viously as part o f  an international consortium 
study screening for mutations in the A B C A 4  
gene.21 The diagnosis o f  A M D  is based on
internationally accepted criteria3; an approxi­
mately equal ratio o f  exudative to atrophic 
A M D  is represented in the patient group. M ost 
patients and controls have been studied in the 
V M D 2 1516 and A B C A 4 21 22 genes.
M utation analysis
G enom ic D N A  was isolated from the periph­
eral b lood  o f A M D  patients and control 
individuals by standard techniques. The entire 
coding sequence o f  the gene and its flanking 5'- 
and 3'-untranslated region (U T R ) were PC R  
amplified in seven segments with the oligonu­
cleotide primer pairs shown in Figure 1 and 
listed in Table 1.
A  total o f  198 German patients and 101 
matched controls were screened for mutations 
with single stranded conformational polymor­
phism (SSCP) analysis. PC R  amplification was 
carried out with Taq-Polymerase (Life Tech­
nologies) in a 25 ^l volume with 1 X PCR 
buffer supplied by the manufacturer. To 
increase sensitivity o f  the SSCP analysis, the 
PC R  products were digested with appropriate 
restriction enzymes to yield fragments <260 bp 
(Table 1). Radiolabelled PCR products were 
separated electrophoretically on a 6% non­
denaturing polyacrylamide gel with or without 
5%  glycerol at 4°C. D N A  fragments displaying 
mobility shifts were sequenced directly.
In all, 241 US and 96 Italian patients, and 
112 US and 39 Italian controls were screened 
by D H P LC . P C R  samples were separated on a 
DNASep column (Transgenomic, Omaha, 
NE, USA) on a Helix H PLC system (Varian 
Instruments, Walnut Creek, CA, U SA), with 
the standard program supplied by the manu­
facturer (Varian).
Exon trapping
The effect o f  the 150G >A transition on RNA 
splicing was evaluated in an exon trapping sys­
tem as described by Rivera et al.22 Briefly, a 333 
bp exonic fragment encompassing this altera­
tion was P C R  amplified from the D N A  o f Ger­
man A M D  patient N o 107 with oligonucle­
otide primers R1-EcoRI-F  (5 '-C C G  G AA 
T T C  A T C  T C A  T C C  A C A  CA G  C C A  C-3') 
and S8-BamHI-R (5 '-C G C  G G A  T C C  CG A 
T C A  C T G  C C A  C T G  T C T  T C -3 '). C on­
structs carrying the normal 150G and the 
mutant 150A allele were selected and trans­
fected into CO S-7 cells. After a 48 hour 
culture, the cells were harvested and total RN A 
was extracted. Two different RT-PCR experi­
ments were performed, the first with two vector 
primers, SD6 (5 '-T C T  G A G  T C A  C C T  G G A  
CAA C C -3 ') and SA2 (5 '-ATC T C A  G T G  
CTA  T T T  G T G  A G C -3 '), and the second 
with vector primer SD6 and exonic primer 
91.s4 (Table 1). As positive control we 
analysed a mutant splice acceptor site 
(IVS20+5G >A) that has a known effect on the 
A B C A 4  transcript.22
Statistical analysis
To test statistically whether there is a relation 
between two categorical variables the Fisher’s 
exact test was used (http://www.matforsk.no/ 
ola/fisher.htm). The sample size required to
A
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1 -30A>C — 27 (6.8%) 14 (6.9%) 44 (9.1%) 13 (5.8%) 14 (7.3%) 5 (6.4%)
1 -4G>A — 0 0 1 (0.2%) 0 0 0
1 150G>A A50A 1 (0.3%) 0 2 (0.4%) 1 (0.5%) 0 0
2 234C>G N78K 1 (0.3%) 0 0 0 0 0
2 296C>T P99L 0 0 1 (0.2%) 0 0 0
2 323G>C S108T 0 0 1 (0.2%) 0 0 0
2 346G>A A116T 5 (1.3%) 2 (1.0%) 11 (2.3%) 3 (1.3%) 15 (7.8%) 4 (5.1%)
2 403A>C T135P 0 0 1 (0.2%) 0 0 0
3 700C>T Q234X 1 (0.3%) 0 0 0 0 0
statistically detect a difference between our 
findings in A M D  patients and controls at a 
given power was computed using an interactive 
web site at http://members.aol.com/johnp71/ 
proppowr.html. The calculations incorporate a 
continuity correction to the usual sample size 
formula based on the normal approximation to 
the binomial distribution.29
Results
CHARACTERISATION OF THE HUMAN G PROTEIN 
COUPLED RECEPTOR-75 (GPR75)
The expression pattern in vitro o f  the tran­
script represented by Unigene cluster Hs. 
40763 was determined by RT-PCR with a 
panel o f  first strand cD N A  from 12 human tis­
sues. Using oligonucleotide primers designed 
from IM AG E clone 222124, we amplified a 
357 bp fragment from cD N A  from retina, 
brain stem, and cerebellum (Fig 2A). No 
amplification products were detected in any 
other tissues, suggesting neuronal expression 
o f  the transcript with the major sites o f  expres­
sion in retina and brain.
O f the five E ST sequences comprising the 
cluster, two derive from IM AG E clone 
222124. Sequencing the full length o f  the clone 
insert resulted in a 2057 bp sequence contain­
ing an A T G  start codon  in a weak context 
(cgaaaATGA)30 followed by an open reading 
frame o f 1623 bp. An in-frame stop codon  was
localised 45 bp upstream o f ATG . We were 
able to extend the sequence 19 bp with 
5'-RACE. Alignment with genom ic sequence 
revealed that the gene consists o f  two exons, at 
least 123 bp and 1732 bp in length, with the 
entire coding sequence contained within the 
larger second exon (acc nos AF303576, 
AF101472) (Fig 1). The two exons are 
separated by an intron o f approximately 4.7 kb 
with the 5'-donor (. . .CAGgtgaga . . .) and 
3'-acceptor splice site (. . .gcatttttgtgtg- 
tagG . . .) conforming to conserved sequences 
required for proper binding o f the active 
spliceosome. The predicted protein product 
consists o f  540 amino acids, has seven 
transmembrane domains and shows hom ology 
to the superfamily o f  G  protein coupled recep­
tors (Fig 3).
We investigated the expression profile fur­
ther by northern blot analysis. Probing with a 
615 bp fragment P C R  amplified from IM AG E 
clone 222124 revealed a 6.6 kb transcript in 
human cerebellum and retina (Fig 2B). Ex­
pression was not detected in lung, the RPE19 
cell line, uterus, liver, heart, or peripheral 
b lood  leucocytes (Fig 2B). The same results 
were obtained with a 270 bp sequence 
amplified from PAC clone dJ302H14 probe 
and located approximately 2.3 kb downstream 
o f  the stop codon  (TAA) (data not shown), 
demonstrating that the transcript contains a
Figure 3 Schematic representation of the GPR75 protein showing the seven putative transmembrane domains and the 
locations of the amino acids affected by the five potentially disease associated variants (black boxes) and two likely 
polymorphisms (white boxes). Each circle represents a single amino acid.
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IVS20 + 5G > A
ex 20
SA2
Figure 4 Evaluation of the consequences of alteration 150G>A. (A) Results of RT-PCR analyses showing identical 
splicing products from both wild type and mutant sequences. The positive control (mutation IVS20+5G>A in the ABCA4 
gene) demonstrates differential splicing between wild type and mutant sequences. A 100 bp sizing ladder, spanning 100-700 
bp, is given. (B-D) Diagrams demonstrating the observed splicing with the position ofoligonucleotide primers (halfarrows) 
and mutant sites (asterisks) shown.
large 3 '-U T R  which has not yet been charac­
terised in its entirety.
MUTATION ANALYSIS
SSCP or D H PL C  analysis o f  the entire coding 
sequence o f  the G PR75  gene (Fig 1) was 
performed in 535 unrelated A M D  patients and 
252 age and ethnically matched controls from 
Germany, the United States, and Italy. This 
analysis identified nine different sequence 
alterations (Table 2 and Fig 3). Six o f  these 
were found in single A M D  patients but not in 
control individuals. These include a guanine to 
adenine transition at position -4  o f  the U T R  
(-4 G > A ), three alterations leading to non­
conservative amino acid substitutions (N78K, 
P99L, T 135P ), one alteration leading to a con­
servative amino acid substitution (S108T), and 
one nonsense mutation, a C to T  transition 
creating a premature stop at codon  234 
(Q 234X ). Analysis o f  D N A  obtained from four 
unaffected sons (aged 36-48 years) o f  the Ger­
man A M D  patient (N o 95) with the Q 234X  
mutation revealed that one has inherited the 
mutation but, at age 47, had a normal ophthal- 
mological examination including the retinas 
(data not shown). Three alterations were found 
in both A M D  patients and control individuals. 
Two o f these, an adenine to cytosine transver­
sion at position -3 0  in the 5 '-U T R  (-30A>C) 
and a guanine to adenine transition at nucle­
otide position 346 leading to a putative 
non-conservative amino acid substitution 
(A 116T), were found in frequencies o f  7.4% 
(117/1574 alleles) and 2.5%  (40/1574 alleles), 
respectively. The frequencies o f  each o f the 
variants were not significantly different be­
tween the A M D  and the control group 
(-30A >C : p = 0.26; A 1 1 6 T :p  = 0.19). A  third 
change involving a G  to A  substitution at
nucleotide position 150 (150G >A) was found 
in one German A M D  patient, two US A M D  
patients, and one US control. This alteration 
does not affect the amino acid sequence but 
does introduce the dinucleotide AG  into the 
D N A  sequence downstream from a stretch o f 
pyrimidine residues.
To determine whether the 150G >A altera­
tion could create a cryptic acceptor splice site, 
we used an exon trapping system to present 
exonic sequence corresponding to the wild 
type and mutant alleles to the splicing machin­
ery in COS7 cells. RT-PCR amplification with 
vector specific oligonucleotide primers SD6 
and SA2 yielded the same 261 bp fragment 
from both the wild type and mutant clones (Fig 
4A , B). Direct D N A  sequencing confirmed 
that both fragments are com posed o f only vec­
tor sequence with both inserts spliced out as a 
result o f  vector related splice donor and accep­
tor sites. A  second RT-PCR experiment was 
performed with vector primer SD6 and exonic 
primer 91.s4. The exonic primer precludes the 
amplification o f  the predominant splice prod­
uct and should allow the detection o f  low 
abundance transcripts. The second experiment 
amplified a 505 bp fragment both from normal 
and from wild type clones (Fig 4A, C). This 
large fragment is completely unspliced and 
includes the full insert and flanking vector 
sequences. The predicted 138 bp fragment 
from the hypothetical cryptic splice site was 
not observed. In the positive control, differen­
tial splicing was observed between the mutant 
IV S20+5G >A  and the wild type sequence in 
the A B C A 4  gene (Fig 4A, D ).
Discussion
In our programme to establish a comprehen­
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predisposition to A M D , we identified a cluster 
o f  five EST sequences derived exclusively from 
retinal cD N A  libraries. The in silico expression 
profile was expanded by in vitro studies 
demonstrating expression in retina and brain 
tissues. Analysis o f  the full length transcript 
and the respective genomic sequence revealed 
a two exon gene, named G P R 75 , that codes for 
a member o f the superfamily o f  G  protein cou­
pled receptors. During the course o f  our work 
G PR75  was cloned independently in the effort 
to identify the gene for Doyne honeycom b reti­
nal dystrophy (D H R D ) and Malattia Leventi- 
nese (M L) on chromosome 2p16.31 Mutation 
analysis in G PR 75 , however, revealed that this 
gene is not underlying the D H R D /M L  pheno- 
type.31 A  single ancestral mutation has since 
been identified in a neighbouring gene, the 
EGF containing fibulin-like extracellular ma­
trix protein-1 (E F E M P 1), in affected individu­
als in D H R D  and M L  families.18
The potential functional properties o f 
G PR 75  as a G  protein coupled receptor in the 
retinal tissue make it a candidate for associ­
ation with the A M D  phenotype. We have stud­
ied the entire coding region and the flanking 
splice site, 5 '-U T R  and 3 '-U T R  sequences in 
535 unrelated A M D  patients and 252 matched 
controls. The analysis identified a total o f  nine 
different sequence alterations o f  which three 
likely represent polymorphic changes. Two of 
these, -30A >C , 346G >A , are present in 
comparable frequencies in A M D  patients and 
control individuals. The third variant 
(150G >A ), found in three A M D  patients and 
one control, was evaluated in an exon trapping 
system for its potential to introduce a cryptic 
splice site; however, no effect on splicing was 
observed. This still leaves uncertainty about 
the potential effect o f  this alteration on gene 
function. Another alteration (-4G >A ) found in 
a single American A M D  patient is also o f 
uncertain significance. This variant occurs 
close to the putative A TG  start codon  but may 
not alter this codon  (cgaaaATGA) substan­
tially, which is already in weak context 
compared to the Kozak consensus sequence.30 
The remaining five alterations, found in single 
A M D  patients, potentially could have adverse 
effects on the protein (N 78K , P99L, S108T, 
T135P, Q 234X ). All the amino acid substitu­
tions affect residues that are in or close to the 
putative transmembrane domains, regions that 
are involved in either ligand binding and/or G  
protein activation in other G  protein coupled 
receptors.26 Furthermore, P99L and T135P 
involve the removal and the addition, respec­
tively, o f  proline residues, which are known to 
induce bends or folds into polypeptide chains 
and could therefore have serious consequences 
for the protein’s three dimensional structure. 
The stop mutation (Q 234X ) occurs in the 
large intracellular loop between the putative 
transmembrane domains V  and VI and results 
in the deletion o f  a substantial portion o f  the 
protein, predictably most o f  this loop, two 
transmembrane domains, and the entire intra­
cellular C terminal end o f the receptor.
While final proof o f  causality is lacking, we 
cannot eliminate the possibility that some
G PR 75  mutations are involved in the observed 
retinal pathology in these rare instances. 
Consequently, a low fraction o f  A M D  cases 
might occur from G PR 75  mutations. The 
histories o f  the five patients with potential del­
eterious changes in the protein showed that 
four, German patients N o 88 and N o 95 and 
US patients N o 119 and N o 26554, have 
extensive soft drusen, retinal pigment epithelial 
detachments, and disciform macular degenera­
tion. The US patient N o 26037, who harbours 
a conservative amino acid substitution 
(S108T), has a different clinical picture with 
geographic atrophy and a positive family 
history o f  AM D . Interestingly, this patient is 
also heterozygous for the D 2177N  variant in 
the A B C A 4  gene21 although the concomitant 
appearance o f these two variants has no clear 
implication on the issue o f association or 
causality. The ages o f  onset o f  visual symptoms 
associated with macular degeneration in the 
five patients range from 63 to 85 years, and one 
heterozygous carrier, the son o f patient N o 95, 
had no retinal abnormalities by examination at 
age 47.
The results o f  this study are comparable to 
previous analyses o f  A M D  patients in the 
V M D 2  gene, that underlies juvenile onset vitel- 
liform macular dystrophy (Best disease).32 33 
Two different studies have found similar low 
frequencies (1 -1 .5% ) o f  V M D 2  mutations in 
A M D  patients.1517 It is unclear, however, 
whether specific V M D 2  mutations lead to an 
A M D  phenotype or whether these findings 
provide evidence for substantial clinical 
heterogeneity in Best disease with some milder 
cases misdiagnosed as A M D  at later stages o f 
the disease. Supporting the latter interpret­
ation is the demonstration o f identical V M D 2  
mutations in patients with Best disease and in 
individuals with adult vitelliform macular dys­
trophy, a phenotypically similar but later onset 
condition.15 16 Unlike V M D 2, however, muta­
tions in G PR75  have not been associated previ­
ously with a retinal phenotype. As a conse­
quence o f  the selection o f genes based on their 
expression profile rather than an association 
with an hereditary retinal disorder, we have no 
information regarding the disease causing 
potential o f  G P R 75 .
Support for an association between GPR75  
variation and A M D  may require screening o f 
even larger cohorts o f  A M D  patients and con­
trols. If we consider the variants which are 
detected in our study with a frequency o f  less 
than 1% in all groups tested, we are left with 
nine sequence alterations in 535 A M D  patients 
(frequency o f  0.84% ) and one variant in 252 
controls (frequency o f 0 .2% ). With a power of 
only 16% these data do not reach statistical 
significance (p = 0.12; one sided Fisher’s exact 
test). To reach a power o f  80%  (at a = 0.05), 
the testing o f approximately 1899 patients and 
894 controls would be required. On the other 
hand, to find association with our present sam­
ple size (535 patients and 252 controls) and 
with the given frequency o f the identified vari­
ations in the control population (0.2% ) (a =
0.05 with 80%  power), the frequency of 
variants in the patient sample would need to be
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10 times higher (2% ) than in the control 
population— that is, the sample size analysed in 
the present study has ample power to detect an 
association that is 2% or greater. The need to 
analyse large cohorts to achieve sufficient 
statistical power to accept or reject the hypoth­
esis o f  an association o f  any disease allele with 
A M D  has also been shown previously in the 
analysis o f  the A B C A 4  gene (for a review, see 
Allikmets34).
Future investigations include identification 
o f  the ligand and the effector molecule(s) and 
the characterisation o f  the function o f  the 
G PR75  receptor in the human retina. In addi­
tion to clarification o f any potential role o f 
G PR75  in A M D , this information may also 
lead to the discovery o f  its role in other retinal 
phenotypes.
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